RxSight, Inc.
About RxSight, Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $134.5M
- Net income
- -$38.9M
- Total assets
- $311.8M
- Market cap
- $207.0M
- Gross margin
- 76.6%
- Operating margin
- -35.8%
- Net margin
- -29.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $134.5M
- Cost of revenue
- $31.5M
- Gross profit
- $103.0M
- Operating expenses
- $151.2M
- Operating income
- -$48.2M
- Income tax
- $66.0K
- Net income
- -$38.9M
- EPS (basic)
- $-0.95
- EPS (diluted)
- $-0.95
Balance sheet
- Total assets
- $311.8M
- Current assets
- $287.5M
- Total liabilities
- $36.1M
- Current liabilities
- $26.3M
- Shareholders’ equity
- $275.7M
Cash flow
- Operating cash flow
- -$15.5M
- Investing cash flow
- $16.9M
- Financing cash flow
- $1.9M
- Net cash flow
- $3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $207.0M
- EPS (diluted)
- $-0.95
- Shares outstanding
- 41.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.9M in FY2025.
- Revenue grew 495% from FY2021 to FY2025.
- Gross margin of 76.6%, net margin -29.0%.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RxSight, Inc..
Write a review
News about RxSight, Inc.
News & sentiment via Polygon.io
